Rofecoxib is a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). It was marketed This was largely based on the VIGOR (Vioxx GI Outcomes Research) study, which compared the .. In November 2011, Merck announced a civil settlement with the US Attorney;s Office for the .. httpsnews...